Last Price | 321.91 | Max Price | 335.97 |
Min Price | 264.06 | 1 Year return | 22.57 |
Sector | Health Care | Subsector | Biotechnology |
Annual report 2020 |
Amgen is a leading human therapeutics company in the biotechnology industry.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness. Amgen’s stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US0311621009/ Symbol: AMGN).
Contact info:Street: One Amgen Center DriveZip Code: 913201799City: Thousand OaksCountry: USAPhone: 8054471000Email: investor.relations@amgen.comWebsite: www.amgen.comCEO: Robert A. BradwayCFO: Michael A. Kelly
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 23,362 | 141,925 | 16.46 % |
2020 | 25,424 | 170,231 | 14.93 % |
2021 | 25,979 | 252,886 | 10.27 % |
2022 | 26,323 | 238,500 | 11.04 % |
2023 | 0 | 0 | 0.00 % |
Analysts: this year best year ever for Amgen
Analysts foresee more revenue Amgen
Analysts expect over 2021 rising revenue Amgen
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Amgen to acquire Five Prime Therapeutics for $1.9B
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
The company's head quarter is located in Thousand Oaks. The company mostly operates in the biotech sector. Robert A. Bradway is operating by ' CEO. Michael A. Kelly runs the company as a CFO. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.
The stock lost over the past 12 months at around 7 percent. Over the period from December 2011 till December 2016 the stock rose on average 132 percent. Amgen's revenues between 2011 and 2015 were very volatile through the time and moved between 17,27 billion dollars and 21,66 billion dollars. Amgen's net incomes between 2011 and 2015 were very volatile and moved between 3,68 billion dollars and 6,94 billion dollars.
Over the past 5 years the American company paid out dividends. Over the past 5 years Amgen's dividend yield was at around 9,48 percent per year.
Amgen had about 17,9 thousand employees at the end of 2015.
At the end of 2015 the American company had a balance sheet of around 71,58 billion dollars. Of the total balance sheet 43,49 billion dollars (60,76 percent) was financed by debt. Last year the biotech company's price/earnings-ratio (PE) was around 17. So the investors valued the stock at 17 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
At the end of 2015 the American company's market capitalization equaled around 119,11 billion dollars. At the end of 2015 the American company had around 754 million stocks listed.
At this page you find all Amgen's financial reports. More information about Amgen can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
21,662
|
22,991
|
22,849
|
23,747
|
23,362
|
25,424
|
Costs |
14,723
|
15,269
|
20,870
|
15,353
|
15,520
|
18,160
|
Profit |
6,939
|
7,722
|
1,979
|
8,394
|
7,842
|
7,264
|
Margin of profit |
32.03
|
33.59
|
8.66
|
35.35
|
33.57
|
28.57
|
ROI |
24.71
|
25.85
|
7.84
|
67.15
|
81.07
|
77.20
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
28,083
|
29,875
|
25,241
|
12,500
|
9,673
|
9,409
|
Debt |
43,366
|
47,751
|
54,713
|
53,916
|
50,034
|
53,539
|
Total assets |
71,449
|
77,626
|
79,954
|
66,416
|
59,707
|
62,948
|
Solvency |
39.30
|
38.49
|
31.57
|
18.82
|
16.20
|
14.95
|
Cash |
31,382
|
38,085
|
41,678
|
29,304
|
8,911
|
10,647
|
Cashflow |
9,731
|
10,354
|
11,177
|
11,296
|
9,150
|
10,497
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.22
|
0.22
|
0.20
|
0.21
|
0.18
|
0.20
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
162.33
|
146.21
|
173.90
|
194.67
|
241.07
|
Eps |
10.24
|
2.69
|
12.62
|
12.88
|
12.31
|
Price/earnings-ratio |
15.85
|
54.35
|
13.78
|
15.11
|
26.15
|
Dividend |
4.00
|
4.60
|
5.28
|
5.80
|
6.40
|
Dividend % |
2.46 %
|
3.15 %
|
3.04 %
|
2.98 %
|
1.99 %
|
Payout % |
0.39
|
1.71
|
0.42
|
0.45
|
0.52
|
Book value |
40.47
|
34.95
|
19.85
|
16.36
|
16.27
|
Market to book |
0.25
|
0.24
|
0.11
|
0.08
|
0.05
|
Cashflow per stock |
14.03
|
15.48
|
17.94
|
15.47
|
18.15
|
Stocks |
738
|
722
|
630
|
591
|
578
|
Market Cap |
119.832.01
|
105.592.86
|
109.487.44
|
115.127.84
|
186.160.55
|
Date
|
Price
|
---|---|
08 Nov 2024
|
321.91
|
05 Nov 2024
|
316.91
|
31 Oct 2024
|
315.54
|
29 Oct 2024
|
317.17
|
23 Oct 2024
|
319.66
|
19 Oct 2024
|
321.66
|
16 Oct 2024
|
325.09
|
14 Oct 2024
|
328.35
|
05 Oct 2024
|
319.66
|
02 Oct 2024
|
320.32
|
27 Sep 2024
|
319.10
|
20 Sep 2024
|
335.95
|
17 Sep 2024
|
335.26
|
13 Sep 2024
|
330.06
|
28 Aug 2024
|
326.93
|
26 Aug 2024
|
328.80
|
23 Aug 2024
|
324.53
|
11 Aug 2024
|
322.49
|
07 Aug 2024
|
328.95
|
05 Aug 2024
|
333.99
|
01 Aug 2024
|
332.47
|
30 Jul 2024
|
332.51
|
26 Jul 2024
|
334.30
|
23 Jul 2024
|
335.97
|
16 Jul 2024
|
330.15
|
10 Jul 2024
|
315.91
|
09 Jul 2024
|
311.46
|
04 Jul 2024
|
309.38
|
02 Jul 2024
|
319.31
|
26 Jun 2024
|
319.31
|